Key TakeawaysThe weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. Tumor ...

A five-year trial of the weight loss drug tirzepatide in Greater Manchester was announced last October ...

Over the past few years, a new class of injectable medications has changed the way obesity is treated. Two drugs—tirzepatide and semaglutide—have shown striking results in helping people lose ...

Glucagon-like peptide 1 receptor agonists may offer neuroprotective and survival benefits beyond blood sugar control.

Adults with type 2 diabetes receiving tirzepatide had significantly greater declines in urine albumin-to-creatinine ratio than those receiving comparators such as placebo or another therapy ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects. Tirzepatide provided superior weight loss when compared with semaglutide ...

Tirzepatide, a once-weekly dual agonist, outperforms long-acting insulin in reducing HbA1c, body weight, and improving cardiovascular markers in Type 2 diabetes patients.

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the ...

In real-world cohort, percentage weight reduction at one year was 3.6, 6.8, and 11.9% with early and late discontinuation and nondiscontinuation, respectively.

Tirzepatide, a new injectable weight-loss drug, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period, compared with placebo, according to ...

Tirzepatide showed superior weight loss efficacy over semaglutide in a phase 3b trial, achieving primary and secondary endpoints. Tirzepatide is the only FDA-approved dual GIP and GLP-1 receptor ...